The AIM‑HI Accelerator Fund is thrilled to announce the 10 semi-finalists selected for the 2025 AIM‑HI Venture Competition. This annual initiative empowers scientist-entrepreneurs in the oncology arena by providing critical seed funding, expert coaching, and access to our global network—fueling the development of breakthrough cancer treatments and accelerating life-saving innovations.
🧬 2025 Semi‑Finalists (in alphabetical order):
- Chiara Biosciences
- Encapsulate
- Gals Bio
- ImmVesica Therapeutics
- NomoCan Pharmaceuticals
- Panakeia
- ResNovas Therapeutics
- Resolute Science
- Saccharo
- Singular Immune
These 10 trailblazing startups are advancing the front lines of cancer innovation. Selected from a highly competitive pool of applications submitted by early-stage oncology companies, each semi-finalist is invited to compete in front of a Judging Committee, which is composed of world-class key opinion leaders in the oncology arena, to determine finalists.
An Investment Committee will conduct detailed due diligence research on the top finalists based on the technology platform merits, cancer patient impact, and potential for return on investment. The company that passes the due diligence process will be recognized at the 2025 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted by AIM-HI, on October 24 in Washington, DC, and be eligible to receive investment from AIM-HI and co-investors. Our three-part Selection, Judging, and Investment Committees consist of world-class life sciences industry professionals, business leaders, and investors.
To learn more about the competition and these bold innovating oncology companies, please click here.
